Study of ACR-2316 for advanced solid tumors
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study tests a new targeted drug called ACR-2316 for people with specific advanced solid tumors that have already been treated but are no longer responding. It aims to see how well the drug works and how safe it is, while looking for a tumor that has certain markers (like a protein or genetic change) that may make the drug more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of advanced cancer (solid tumor) that has spread or come back after treatment, and has been confirmed by a biopsy
- You have had no more than 3 prior cancer treatments (lines of therapy) for this disease
- You are well enough to take care of yourself and get around (ECOG 0-1), and your doctor expects you to live at least 3 more months
- Your cancer can be measured on scans by a standard method (RECIST), and you must have at least one measurable tumor
- Your kidney, liver, and bone marrow function must be adequate (checked by blood tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ACR246 for people with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see if the drug can shrink tumors.
This is an early-stage trial testing a new drug called CS231295 in people with advanced cancers (like lung, pancreatic, or brain tumors) that have stopped responding to standard treatments. The study aims to find the right dose and learn how well the drug works.
This study tests a new drug, CRB-601-01, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and can help shrink tumors.
This trial tests an experimental drug called CS231295 for people with advanced solid tumors that have not responded to standard treatments. The purpose is to study safety and find out if the drug can shrink tumors.
This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Hear when a new Specific Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.